EntryPoint Capital LLC Boosts Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

EntryPoint Capital LLC lifted its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) by 328.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 53,443 shares of the company’s stock after acquiring an additional 40,964 shares during the quarter. EntryPoint Capital LLC’s holdings in Roivant Sciences were worth $632,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Nordea Investment Management AB boosted its position in Roivant Sciences by 22.5% in the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock worth $3,306,000 after purchasing an additional 52,031 shares during the last quarter. TOMS Capital Investment Management LP purchased a new position in shares of Roivant Sciences in the 3rd quarter worth about $46,333,000. Barclays PLC boosted its holdings in shares of Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company’s stock worth $5,302,000 after buying an additional 75,609 shares during the last quarter. Loomis Sayles & Co. L P grew its position in Roivant Sciences by 13.3% during the third quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock valued at $45,147,000 after buying an additional 458,601 shares during the period. Finally, Retirement Systems of Alabama increased its holdings in Roivant Sciences by 26.9% during the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock worth $6,116,000 after buying an additional 112,286 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Trading Up 0.4 %

Shares of ROIV stock opened at $10.83 on Tuesday. The firm’s 50 day moving average is $10.79 and its 200 day moving average is $11.45. The stock has a market capitalization of $7.73 billion, a P/E ratio of -72.20 and a beta of 1.26. Roivant Sciences Ltd. has a 12 month low of $9.93 and a 12 month high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, equities analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Insider Buying and Selling

In other news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total value of $1,128,000.00. Following the completion of the transaction, the chief operating officer now directly owns 732,294 shares in the company, valued at approximately $8,260,276.32. This trade represents a 12.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares of the company’s stock, valued at approximately $1,702,843.52. This represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 2,439,640 shares of company stock valued at $27,451,035. Corporate insiders own 7.90% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Tuesday, February 11th. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $18.08.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.